Hologic (NASDAQ: HOLX) reported Q3 EPS of $0.75, $0.37 better than the analyst estimate of $0.38. Revenue for the quarter came in at $822.9 million versus the consensus estimate of $616.69 million.

“Our strong third quarter financial results reflect the incredible contributions the Hologic team is making in the fight against the COVID-19 pandemic, and demonstrate the value of our unique set of businesses in a time of great macroeconomic uncertainty,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “I’m so proud of the incredible teamwork and work ethic that brought our two tests to market quickly, increased production capacity significantly, and installed an unprecedented number of new Panther® instruments to help our laboratory customers deliver test results when and where they are needed. Inspired by our purpose of enabling healthier lives, our team knocked down barriers by the day to deliver way beyond what we could even imagine.”

GUIDANCE:

Hologic sees Q4 2020 EPS of $0.95-$1.15, versus the consensus of $0.69. Hologic sees Q4 2020 revenue of $0.925-1.025 billion, versus the consensus of $0.8155 billion.

For earnings history and earnings-related data on Hologic (HOLX) click here.